Display Settings:

Format
Items per page

Send to:

Choose Destination

Results: 1 to 20 of 42

1.

Murine

MedGen UID:
108834
Concept ID:
C0591833
Pharmacologic Substance
2.

Graft-versus-host disease, susceptibility to

Transplantation of hematopoietic stem cells is a successful therapy for some tumors derived from bone marrow precursors, such as certain leukemias and lymphomas, and it can be used to cure some primary immunodeficiencies and inherited hematopoietic stem-cell diseases. One of the major complications of allogeneic bone marrow transplantation is graft-versus-host disease (GVHD), in which mature donor T cells that contaminate the allogeneic bone marrow recognize the tissues of the recipient as foreign, causing a severe inflammatory disease characterized by rashes, diarrhea, and liver disease. GVHD is particularly virulent when there is a mismatch of a major major histocompatibility complex (MHC) class I or class II antigen. Most transplants are therefore undertaken only when the donor and recipient are HLA-matched sibs or, less frequently, when there is an HLA-matched unrelated donor. However, GVHD also occurs in the context of disparities between minor histocompatibility antigens, and immunosuppression must be used in every stem-cell transplant (summary by Janeway et al., 2005). At the core of the immunogenetic basis for GVHD is the diversity of HLA, killer immunoglobulin-like receptors (KIRs; see 604936), and cytokine genes. HLA class I molecules function as ligands for natural killer cell inhibitory KIRs, indicating that GVHD results from a complex interplay between innate and adaptive immune responses. Cytokines may modulate the intensity of tissue injury and inflammation in GVHD, and therefore cytokine polymorphisms in either patient or donor or both may explain individual risks of GVHD (review by Petersdorf and Malkki, 2006). [from OMIM]

MedGen UID:
482307
Concept ID:
C3280677
Finding
3.

Graft versus host disease

The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION. [from MeSH]

MedGen UID:
9082
Concept ID:
C0018133
Disease or Syndrome
4.

Cannabinoid

terpene constituents of Cannabis. [from CRISP]

MedGen UID:
737
Concept ID:
C0006864
Pharmacologic Substance
5.

Complication Aspects

Used with diseases to indicate conditions that co-exist or follow, i.e., co-existing diseases, complications, or sequelae. [from MeSH]

MedGen UID:
223946
Concept ID:
C1171258
Pathologic Function
6.

Hyperplasia

An abnormal increase in the number of cells in an organ or tissue. [from NCI]

MedGen UID:
43784
Concept ID:
C0020507
Pathologic Function
7.

Body Weight decreased

Decrease in existing BODY WEIGHT. [from MeSH]

MedGen UID:
21911
Concept ID:
C0043096
Finding
8.

Disease

Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function. [from NCI]

MedGen UID:
4347
Concept ID:
C0012634
Disease or Syndrome
9.

disease

An alteration of health status resulting from a physiopathological mechanism, and having a homogeneous clinical presentation and evolution and homogeneous therapeutic possibilities. Excludes developmental anomalies. [from ORDO]

MedGen UID:
798428
Concept ID:
CN204926
Disease or Syndrome
10.

Weight loss

Reduction inexisting body weight. [from HPO]

MedGen UID:
504965
Concept ID:
CN001653
Finding
11.

Life Threatening

A situation that imperils the existence of an entity. [from NCI]

MedGen UID:
415288
Concept ID:
C2826244
Finding
12.

Diamond-Blackfan anemia 1

MedGen UID:
390966
Concept ID:
C2676137
Disease or Syndrome
13.

Thrombocytopenia, X-linked

The WAS-related disorders, which include Wiskott-Aldrich syndrome, X-linked thrombocytopenia (XLT), and X-linked congenital neutropenia (XLN), are a spectrum of disorders of hematopoietic cells, with predominant defects of platelets and lymphocytes caused by pathogenic variants in WAS. WAS-related disorders usually present in infancy. Affected males have thrombocytopenia with intermittent mucosal bleeding, bloody diarrhea, and intermittent or chronic petechiae and purpura; eczema; and recurrent bacterial and viral infections, particularly recurrent ear infections. At least 40% of those who survive the early complications develop one or more autoimmune conditions including hemolytic anemia, immune thrombocytopenic purpura (ITP), immune-mediated neutropenia, arthritis, vasculitis of small and large vessels, and immune-mediated damage to the kidneys and liver. Individuals with a WAS-related disorder, particularly those who have been exposed to Epstein-Barr virus (EBV), have an increased risk of developing lymphomas, which often occur in unusual, extranodal locations such as the brain, lung, or gastrointestinal tract. Males with XLT have thrombocytopenia with small platelets; other complications of Wiskott-Aldrich syndrome, including eczema and immune dysfunction, are mild or absent. [from GeneReviews]

MedGen UID:
326416
Concept ID:
C1839163
Disease or Syndrome
14.

Diamond-Blackfan anemia

Diamond-Blackfan anemia (DBA) in its classic form is characterized by a profound isolated normochromic and usually macrocytic anemia with normal leukocytes and platelets, congenital malformations in approximately 50% of affected individuals, and growth retardation in 30% of affected individuals. The hematologic complications occur in 90% of affected individuals during the first year of life (median age of onset: 2 months). Eventually, 40% of affected individuals are corticosteroid dependent, 40% are transfusion dependent, and 20% go into remission. The phenotypic spectrum ranges from a mild form (e.g., mild anemia; no anemia with only subtle erythroid abnormalities; physical malformations without anemia) to a severe form of fetal anemia resulting in nonimmune hydrops fetalis. DBA is associated with an increased risk for acute myelogenous leukemia (AML), myelodysplastic syndrome (MDS), and solid tumors including osteogenic sarcoma. [from GeneReviews]

MedGen UID:
266045
Concept ID:
C1260899
Congenital Abnormality
15.

Severe

A term used to describe cells that look abnormal under a microscope. These cells are more likely to grow and spread quickly than cells in low-grade cancer or in growths that may become cancer. [from NCI]

MedGen UID:
104640
Concept ID:
C0205082
16.

Lymphoid hyperplasia, NOS

A benign or malignant, diffuse and/or follicular lymphocytic proliferation. [from NCI]

MedGen UID:
90735
Concept ID:
C0333997
Disease or Syndrome
17.

Acute

Symptoms or signs that begin and worsen quickly; not chronic. [from NCI]

MedGen UID:
61381
Concept ID:
C0205178
18.

Tetrahydrocannabinol

an organic chemical extracted from Marihuana [from CHV]

MedGen UID:
21110
Concept ID:
C0039663
Pharmacologic Substance
19.

Cannabinoid Receptor Modulators

Compounds that interact with and modulate the activity of CANNABINOID RECEPTORS. [from MeSH]

MedGen UID:
488428
Concept ID:
C3494475
Pharmacologic Substance
20.

Cannabinoid Receptor Antagonists

Compounds that inhibit or block the activity of CANNABINOID RECEPTORS. [from MeSH]

MedGen UID:
473700
Concept ID:
C2927149
Pharmacologic Substance

Display Settings:

Format
Items per page

Send to:

Choose Destination

Supplemental Content

Find related data

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...